Study S001795

The Effects of Tirzepatide Use on Muscle and Vascular Function Among Obese Older Adults

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06811324
Study type: INTERVENTIONAL
Phase: PHASE2
Masking: NONE
Status: RECRUITING
Enrollment: 20
Start: 2026-04-01
Primary completion: 2027-04-01
Lead sponsor: The University of Texas Health Science Center at San Antonio
Conditions: Obesity Prevention; Sarcopenia in Elderly; Cardiovascular Function; GLP - 1; Weight Loss
Interventions: DRUG:Tirzepatide
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Appendicular lean muscle mass [6 months]
Muscle Strength [6 months]
Lower Extremity Functional Capacity [6 months]

Linked records (6)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0006708	Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Neeland IJ, Diabetes, obesity & metabolism	2024	Narrative review	PMID 38937282 DOI	registry reference BACKGROUND:38937282
R0007405	Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Wadden TA, Nature medicine	2023	Randomized trial	PMID 37840095 DOI	registry reference BACKGROUND:37840095
R0012668	GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes. Marx N, Circulation	2022	Narrative review	PMID 36508493 DOI	registry reference BACKGROUND:36508493
R0016833	Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes. Kaneko S, TouchREVIEWS in endocrinology	2022	Other trial	PMID 35949358 DOI	registry reference BACKGROUND:35949358
R0006977	Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US. Eberly LA, JAMA health forum	2021	Randomized trial	PMID 35977298 DOI	registry reference BACKGROUND:35977298
R0013656	Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. Frías JP, The New England journal of medicine	2021	Randomized trial	PMID 34170647 DOI	registry reference BACKGROUND:34170647